Shigeki Miyamoto

Contact Information
608-262-9281 (office); 608-265-8595 (lab)
7551 WIMR II


BA, 1985, Biochemistry/Molecular Biology, University of California-Santa Cruz
PhD, 1990, Cancer Research/Endocrinology, University of California at Berkeley
Postdoctoral Research, Salk Institute, San Diego


Professor of Oncology
Developmental Therapeutics Program Leader, UW Carbone Cancer Center

Research Description

Over the last two decades, the Miyamoto lab has pursued a variety of research interests centered around cell signaling and asked “what happens when cells are no longer able to communicate effectively?” Most of the current research is focused on understanding the NF-κB signaling pathway as a model. Our lab, and others, have shown that NF-κB is key in promoting cell survival (anti-apoptotic), normal immune system development, stress response, early embryonic development, cell adhesion, and tumor metastasis.

With regard to the NF-κB model, our lab has two overarching research interests. First, we are interested in characterizing how nuclear stress conditions, such as DNA damage, induce signaling events in the cytoplasm. Second, we are interested in how cancer cells use signaling mechanisms for their growth and survival advantages to evade anticancer drug effects.  We are currently focusing on the NF-κB signaling system as an important paradigm to increase our understanding of these processes.

National Committees

Member, National Institutes of Health Tumor Microenvironment Study Section, 2011-2017

Perform a PubMed Search for Dr. Miyamoto’s Publications